Related Experiment Video
Updated: Jul 19, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
[Intracranial primary malignant lymphoma following Behçet's disease--case report]
K Harada1, K Ohtsuru, K Nakayama
1Department of Neurosurgery, Omuta City Hospital.
No to Shinkei = Brain and Nerve
|November 1, 1992
Summary
This case report details a rare instance of primary central nervous system lymphoma in a patient with Behçet disease treated with colchicine. The study suggests a potential link between colchicine-induced immunosuppression and lymphoma development.
Area of Science:
- Neurology
- Oncology
- Rheumatology
Background:
- Behçet disease is a multisystem inflammatory disorder.
- Primary central nervous system lymphoma (PCNSL) is a rare malignancy.
- Colchicine is used to treat Behçet disease but can cause immunosuppression.
Observation:
- A 43-year-old female with Behçet disease developed uveitis and was treated with colchicine.
- She later presented with neurological symptoms and was diagnosed with B-cell type diffuse large cell lymphoma in the left cerebellar hemisphere.
- No systemic lymphoma or other abnormalities were detected.
Findings:
- The patient was treated with radiation and prednisolone, leading to recovery without neurological deficits.
- This represents a potential new association between colchicine treatment for Behçet disease and the development of PCNSL.
- Lymphocyte response to phytohemagglutinin stimulation was reduced.
Implications:
- This case highlights a possible adverse effect of colchicine in immunosuppression, potentially increasing lymphoma risk.
- Further research is needed to explore the relationship between colchicine, immunosuppression, and lymphomagenesis in Behçet disease patients.
- Clinicians should consider this potential risk when managing Behçet disease with colchicine.
